Pricing Log in Create free account
Saturday 17 October 2026 Export VTGN’s income statement to Excel — free account

VistaGen Therapeutics, Inc.

VTGN Healthcare Biotechnology

VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025. In the quarter to June 2026, revenue grew 504.9%, EPS grew 36.2% and free cash flow grew 22.2%, each against the same quarter a year earlier.

0.20 0.01 −4.76%
Market cap
$9.5M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
3/9
Altman Z
−16.79
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

VistaGen Therapeutics, Inc. (VTGN) Business Profile

Updated before January 2025

Company Overview

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders. Founded in 1998 and headquartered in South San Francisco, California, VistaGen focuses on addressing unmet medical needs in mental health by leveraging its expertise in neuroscience and drug development. The company is led by a team of experienced professionals, including CEO Shawn Singh, who has been instrumental in driving the company’s strategic vision and operational growth. Other key members of the leadership team include Dr. Mark Smith, Chief Medical Officer, and Jerry Dotson, Chief Financial Officer. Together, they bring decades of experience in biopharmaceutical research, clinical development, and commercialization.

Core Business Segments

VistaGen Therapeutics operates primarily in the CNS therapeutics space, with a focus on developing novel treatments for anxiety, depression, and other mental health disorders. The company’s core business segments include:

1. Anxiety and Depression Therapies

  • PH94B (Fasedienol): A first-in-class, rapid-onset nasal spray designed to treat social anxiety disorder (SAD). PH94B is currently in late-stage clinical trials and has shown promise as a non-sedating alternative to traditional anti-anxiety medications.
  • PH10: Another innovative nasal spray in development for major depressive disorder (MDD). PH10 is designed to provide rapid relief without the systemic side effects associated with oral antidepressants.

2. CNS Drug Development Platform

  • VistaGen leverages its proprietary drug development platform to identify and advance novel CNS therapies. This platform integrates cutting-edge neuroscience research with advanced drug discovery technologies to address complex mental health challenges.

3. Adjunctive Therapies

  • The company is also exploring the potential of its therapies as adjunctive treatments to enhance the efficacy of existing CNS medications. This approach aims to provide more comprehensive solutions for patients with treatment-resistant conditions.

Business Model

VistaGen’s business model is centered on the development and commercialization of innovative CNS therapies. The company generates revenue through:

  • Clinical Development Partnerships: Collaborating with academic institutions, research organizations, and pharmaceutical companies to advance its drug candidates.
  • Licensing Agreements: Licensing its proprietary technologies and drug candidates to third parties for further development and commercialization.
  • Future Product Sales: Once its therapies receive regulatory approval, VistaGen plans to generate revenue through direct sales and distribution agreements.

The company’s approach emphasizes patient-centric innovation, aiming to deliver safe, effective, and accessible treatments for mental health disorders.

Strategic Direction

VistaGen is committed to transforming the treatment landscape for CNS disorders. Its strategic priorities include:

  • Advancing Clinical Trials: Completing late-stage clinical trials for PH94B and PH10 to secure regulatory approval and bring these therapies to market.
  • Expanding the Pipeline: Investing in research and development to identify new drug candidates and expand its portfolio of CNS therapies.
  • Global Market Expansion: Establishing partnerships and distribution networks to reach patients worldwide.
  • Sustainability Goals: Incorporating sustainable practices into its operations, including reducing its environmental footprint and promoting ethical research practices.

Competitive Landscape

VistaGen operates in a highly competitive biopharmaceutical market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Big Pharma: Companies like Pfizer, Eli Lilly, and Johnson & Johnson, which have extensive CNS portfolios.
  • Biotech Firms: Emerging players such as Sage Therapeutics and Axsome Therapeutics, which are also focused on developing innovative mental health treatments.
  • Generic Drug Manufacturers: Providers of low-cost alternatives to branded CNS therapies.

VistaGen differentiates itself through its focus on rapid-onset, non-systemic therapies that address unmet needs in mental health.

Risk Factors

Like any biopharmaceutical company, VistaGen faces several risks, including:

  • Regulatory Challenges: Delays or failures in obtaining FDA approval for its drug candidates could impact its ability to commercialize its therapies.
  • Market Dependence: The company’s success is heavily reliant on the commercial viability of PH94B and PH10.
  • Supply Chain Disruptions: Dependence on third-party manufacturers and suppliers exposes VistaGen to potential disruptions in the production and distribution of its therapies.
  • Financial Risks: As a clinical-stage company, VistaGen relies on external funding and may face challenges in securing sufficient capital to sustain its operations.

Recent Developments

VistaGen has made significant progress in advancing its clinical programs and corporate strategy. Recent highlights include:

  • Clinical Trial Updates: Positive interim results from Phase 3 trials of PH94B for social anxiety disorder, demonstrating its potential as a game-changing therapy.
  • Strategic Partnerships: Collaborations with leading research institutions to accelerate the development of its CNS pipeline.
  • Corporate Milestones: Strengthening its leadership team and securing additional funding to support its growth initiatives.
  • Global Developments: The COVID-19 pandemic has underscored the importance of mental health, creating increased demand for innovative CNS therapies like those developed by VistaGen.

Investment Considerations

Investors considering VistaGen Therapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: A robust portfolio of first-in-class CNS therapies with significant market potential.
  • Experienced Leadership: A seasoned management team with a proven track record in biopharmaceutical development.
  • Growing Market: Increasing awareness and demand for mental health treatments create a favorable market environment.

Risks

  • Regulatory Uncertainty: The outcome of clinical trials and regulatory reviews remains uncertain.
  • Financial Dependence: Reliance on external funding poses a risk to long-term sustainability.
  • Competitive Pressure: Intense competition from established players and emerging biotech firms.

Conclusion

VistaGen Therapeutics is well-positioned to become a leader in the CNS therapeutics market. With a focus on innovative, patient-centric solutions, the company is addressing critical unmet needs in mental health. While challenges remain, including regulatory and financial risks, VistaGen’s strong pipeline, experienced leadership, and strategic vision provide a solid foundation for future growth. As the demand for mental health treatments continues to rise, VistaGen is poised to make a meaningful impact on the lives of patients worldwide.